Achieve life sciences announces presentation of cytisinicline data at the 21st annual society for research on nicotine & tobacco (srnt-e) virtual conference

Seattle, wa & vancouver, bc / accesswire / september 14, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming society for research on nicotine & tobacco (srnt-e) conference to be held virtually september 15-17, 2021. presentation details "cytisinicline may benefit smokers who previously failed to quit smoking with varenicline: a subgroup analysis of the orca-1 trial" a subgroup analysis from the orca-1 phase 2 study of smokers who had previously failed chantix® (varenicline) demonstrated a week 4 abstinence rate of 51.3% upon treatment with cytisinicline using the three times daily (tid) regimen, compared with 15.8% with placebo (p= 0.009).
ACHV Ratings Summary
ACHV Quant Ranking